TRIAL DETAIL

Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors

Drug:
Trial Name:
Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 06/16/2007
Age of Trial (yrs) 15
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor
Strategy:
Block KIT Signal Path
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
XL147-001
Sponsor:
Exelixis
Patient Contact:
Exelixis Contact Line
Contact email:
Contact Phone:
866-939-4041
Randomized:
IV or Oral:
Oral
Trial Notes:
The purpose of this study is to evaluate the safety and tolerability of XL147 in subjects with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.

Trial Links

Trial Results

 
 
 

Drug Information

Exelixis pipeline
 

Trial Sites

Name
Address
City
State
Zip
Country
450 Brookline Ave
Boston
MA
02215-5450
USA
119-129
Barcelona
08035
Spain
Dallas
TX
75246
USA